< Back to Team

TJ Cradick, PhD


Excision BioTherapeutics
Chief Science Officer

Dr. TJ Cradick is a recognized expert in genome editing technologies. Dr. Cradick has developed nucleases, as well as genome editing and gene therapy reagents and methods for CRISPR/Cas nuclease, TAL Effector Nucleases (TALENs) and Zinc Finger Nucleases (ZFNs), both in his academic work at University of Iowa and the Georgia Institute of Technology, and in industry at Sangamo Therapeutics and CRISPR Therapeutics. He has co-authored manuscripts on each of these nuclease technologies and on developing bioinformatics web tools including ZFN-Site, PROGNOS, SAPTA and COSMID. He also led the first work on the use of engineered nucleases as a therapeutic strategy for targeting Hepatitis B virus, and co-authored the first publication on the topic.   

Back to top